Age-Related Macular Degeneration (AMD)
- Age-Related Macular Degeneration Preferred Practice Patterns 2024
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial
- The Age-Related Eye Disease 2 Study: Micronutrients in the Treatment of Macular Degeneration
- Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration
- Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab
- Interim Results of the Phase III Portal Extension Trial of the PDS with Ranibizumab in nAMD
- FARETINA-AMD: Early Outcomes After Initiation of Faricimab for nAMD
- The Promise of TKIs in nAMD and DR
- Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes
- Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond
- Age-Related Macular Degeneration (AMD) for Patients
- Impact of Anti-VEGF on Vision Outcomes in nAMD: 6-Year Analysis of the AAO IRIS® Registry
- TENAYA/LUCERNE: Two-Year Results from the Phase 3 nAMD Trials of Faricimab with T&E Dosing
- Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
- What AREDS means for you?
- Mayo Clinic: Dry Macular Degeneration
- Understanding Your AMD – Patient Handout
- Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration – Patient Handout
- Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education
Cataract and/or Refractive Surgery
- AAO Refractive Surgery Preferred Practice Patterns 2024
- Saving of Time Using a Software-Based versus a Manual Workflow for Toric Intraocular Lens Calculation and Implantation
- AAO Cataract in the Adult Eye Preferred Practice Pattern 2021
- Cataract and Refractive Lens Exchange Questionnaire
- Post-Refractive IOL Calculator
- American Society of Cataract and Refractive Surgery
- Toric IOL Calculator
- Preparing for Cataract Surgery – Postoperative Concerns – Patient Handout
Conjunctivitis
- Conjunctivitis: What is Pink Eye? – Patient Information
- Help Protect Yourself From Getting & Spreading Pink Eye (Conjunctivitis) – Patient Handout
Demodex Blepharitis
- Multidisciplinary perspectives in Demodex blepharitis: A new view of treatment from clinical, payer, and patient perspectives
- Prevalence of Demodex Blepharitis in US Eye Care Clinic Patients as Determined by Collarettes: A Pathognomonic Sign
- Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis
Diabetic Macular Edema (DME)
- Eye Care of the Patient with Diabetes Mellitus
- Faricimab Treat-and-Extend for Diabetic Macular Edema. Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
- Intravitreal Aflibercept 8 mg for Diabetic Macular Edema. Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial
- Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial
- Impact of the Dexamethasone Implant on Slowing DR Progression: Post Hoc Analysis of the MEAD Study
- Diabetic Retinopathy Preferred Practice Pattern
- Long-term Treatment Patterns for DME: 6-Year Follow-Up in the IRIS® Registry
- PHOTON: Intravitreal Aflibercept 8 mg in DME: 48-Week Results, Phase 2/3 Trial
- Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema – Patient Handout
- Facts About Macular Edema
- 5 Year Outcomes After Aflibercept, Bevacizumab, or Ranibizumab for DME: Protocol T Extension Study
Diabetic Retinopathy
- Diabetic Retinopathy Preferred Practice Pattern
- Intravitreal Aflibercept for the Treatment of Diabetic Retinopathy Among Patients Who Completed PANORAMA: 1-Year Outcomes from the VOYAGE Extension Study
- Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial
- Understanding Diabetic Retinopathy – Patient Handout
- Diabetic Retinopathy Clinical Research Network Publications
- Diabetic Retinopathy: Causes, Symptoms, Treatment
- Protocol W: Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
- Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy
Geographic Atrophy
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
- Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial
- Unlocking geographic atrophy
- Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration
- Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
- Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel
- Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3
General
- FDA Prescribing Information for Professionals
- ICD-10-CM for Ophthalmology
- EyeNet Magazine
- National Institutes of Health Guidelines on Human Subjects Research
- AAO Preferred Practice Patterns
- Vicchrilli S. Savvy coder: telemedicine during the public health emergency.
- AAO.org: Home Eye Test for Adults
Glaucoma
- Primary Open-Angle Glaucoma Preferred Practice Patterns 2025
- Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
- Ocular effects of Rho kinase (ROCK) inhibition: a systematic review
- Netarsudil 0.02% Alters Episcleral Venous Flowrates: A Clinical Trial Using Erythrocyte-Mediated Angiography
- Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review
- Preservatives and ocular surface disease: A review
- The Glaucoma Foundation: Preservative-Free Glaucoma Eye Drops
- Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
- National Eye Institute: Glaucoma
- Bimatoprost Implant. Prescribing Information
- Microinvasive Glaucoma Surgery (MIGS)
- Xen Gel Stent: Directions for Use
- American Glaucoma Society
Inherited Retinal Diseases
- Genetic testing and diagnosis of inherited retinal diseases
- AAO Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations – 2022
- Patient Information – Inherited Retinal Diseases
- Foundation Fighting Blindness
Macular Disorders
Macular Telangiectasia
- What Is Macular Telangiectasia?
- Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2
- Revakinagene taroretcel-lwey. Package Insert
- Macular Telangiectasia Type 2: A Comprehensive Review
Neurotrophic Keratitis
- Nerve Growth Factor Treatment for Neurotrophic Keratopathy in the IRIS® Registry
- Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System
- Neurotrophic Keratitis: Pharmacological Treatments
- Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
- Cenegermin Prescribing Information
- Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
- Neurotrophic keratopathy: An updated understanding
- Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy
Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD. Recommendations for Eculizumab, Inebilizumab, and Satralizumab
- Contemporary management challenges in seropositive NMOSD
- Guthy Jackson Foundation
- Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
- Neuromyelitis Optica Spectrum Disorder
- The Sumaira Foundation for NMO
Ocular Surface and Lid Margin Disease
- Improved Dry Eye Drugs for 2025 and Beyond
- TFOS DEWS III Diagnostic Methodology
- A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)
- Managing dry eye in 2025: Think bigger picture, multisystem – Optometry Times
- NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction
- TFOS Lifestyle: Impact of nutrition on the ocular surface
- Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists
- Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study
- Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
- AAO EyeWiki: Meibomian Gland Dysfunction (MGD)
- Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
- Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial
- A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
- Dry Eye: Patient Information
- American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome
- American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis
- Sjögren’s Syndrome Foundation
Plasminogen Deficiency
- Plasminogen Deficiency Foundation
- NORD: Congenital Type 1 Plasminogen Deficiency
- Rare Coagulation Disorders: Plasminogen Deficiency
- Interactions of the Fibrinolytic And Innate Immune Systems
- Treatment of Ligneous Conjunctivitis with Plasminogen Eyedrops
- Plasminogen, human-tvmh for the treatment of children and adults with plasminogen deficiency type 1
- Treating Type 1 Plasminogen Deficiency
- Case Report: Treating Respiratory Lesions with Plasminogen, human-tvmh
Presbyopia
- Presbyopia Treatment
- Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
- What Is Presbyopia? (Patient Material)
- A Review of Pharmacological Presbyopia Treatment
- Treatments for presbyopia coming soon
Retinal Vascular Diseases (RVO)
- Infographic: study design of the QUASAR randomised trial of aflibercept 8 mg in retinal vein occlusion
- Retinal Vein Occlusions PPP 2024
- BALATON and COMINO 72-Week Results: Faricimab T&E Dosing for Retinal Vein Occlusion
- Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion
- Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study
- Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
- Branch Retinal Vein Occlusion Information for Patients
- Central Retinal Vein Occlusion Information for Patients
- Understanding Your Retinal Vein Occlusion (RVO) – Patient Handout
Thyroid Eye Disease (TED)
- A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease
- Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells
- MON-360 Lonigutamab (Anti-IGF-1R Monoclonal Antibody) Reduces IGF-1-Mediated Hyaluronan Production in Thyroid Eye Disease Orbital Fibroblasts
- Efficacy and Safety of Veligrotug (VRDN-001), a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease (TED): THRIVE Phase 3 Topline Results
- Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
- Thyroid Eye Disease: Navigating Diagnosis and Treatment
- Patient Brochures
- Patient Material: Examining the Optics of TED
Uveitis
- A Guide to Ocular Inflammatory Disease. For Patients
- Uveitis. For Patients
- Treatment of Uveitis
- Anterior uveitis for the comprehensive ophthalmologist
- Development of Classification Criteria for the Uveitides: SUN
- Preparing for Your Appointment – Patient Handout
